Ipca Labs Q2 FY26 net profit jumps 25% YoY on strong growth

Profit growth above 25%EBITDA margin expansionExceptional itemResults View source PDF Explain this filing

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.7%Reaction day

₹1330.00

prior close

₹1329.80

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.3%-2.3% vs market

Pharmaceuticals peers, median of 157sector-0.0%-2.6% vs sector

On the reaction day the stock moved 2.3 pts less than Nifty Midcap 150 and 2.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.6

15m

+0.0

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.7-0.3-2.3-0.0-2.6

Next day

+8.4-0.3+8.7-0.5+8.9

+9.5+0.4+9.2-0.4+9.9

+6.8-0.2+7.0-1.1+7.9

+8.3+0.1+8.2-1.4+9.6

+7.4+0.1+7.4-1.6+9.0

+6.6-1.4+8.0-3.3+10.0

15d

+9.4-1.2+10.6-3.4+12.8

+8.2-1.2+9.4-4.3+12.5

+13.2-2.1+15.3-6.9+20.0

+10.8-2.3+13.1-8.8+19.6

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ipca Labs Q2 FY26: Standalone revenue Rs 1,930 crores up 7%, net profit Rs 305 crores up 25% YoY. Consolidated revenue Rs 2,557 crores up 9%, net profit Rs 283 crores up 23%. Standalone EBITDA margin expanded to 25.46% from 22.89% last year. H1 FY26 standalone net profit up 26% to Rs 567 crores. Consolidated results include Rs 58 crore exceptional charge for European Commission fine interest at subsidiary Unichem Labs, which was fully settled in October 2025.

Likely market impact

Solid revenue and profit growth with margin expansion. EU fine already paid. New Unichem Ireland acquisition adds to subsidiary base.